Davita Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Davita Inc (DVA) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Davita Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 14,010M vs 83,819M combined for tracked competitors (14.3% combined share).
- Trending: Latest-quarter revenue run-rate is holding steady (+1.5% annualized vs trailing 12 months), vs holding steady (+1.8%) for its tracked peer group.
- Growth: Davita Inc generated 5.2% revenue growth year over year in Q2 2026, vs 4.6% for its tracked competitors combined.
- Profitability: Its 9.7% net margin compares with 10.2% for the peer group.
- Scale: Davita Inc ranks #6 of 51 companies by market capitalization in the Healthcare Facilities industry, holding 4.6% of industry market cap.
- Peer revenue share: Davita Inc accounted for 14.3% of combined revenue among its tracked peer group, up from 14.2% a year earlier.
- Peer differentiation: Revenue per employee of $0.18M compares with $0.23M for the peer group (0.8x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
DVA Sales vs. its Competitors, Q2 2026
Davita Inc reported revenue growth of 5.17 % year on year in Q2 2026, above its competitors' combined revenue growth of 4.63 %.
With a net margin of 9.66 %, Davita Inc reported lower profitability than its competitors (10.23 %).
Davita Inc generated 14.28 % of the combined sales of its peer group, up from 14.22 % a year earlier.
Davita Inc vs. its Competitors, Q2 2026
Revenue growth, year on year
Net income growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Davita Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Davita Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (3) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (8) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (7) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Davita Inc's competitor groups requires a Commercial License.
For context: the Healthcare Facilities industry grew revenue 14.7% year over year, combined, vs 5.2% for Davita Inc. Davita Inc's share of combined industry revenue moved from 3.28% to 3.01%, a loss of 0.27 percentage points.
Davita Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Davita Inc | Yes | Yes | Yes | No |
| Competitors combined (20) | ||||
| High-Confidence Competitors (3) | ||||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 100.00 % (8 of 8) | 100.00 % (8 of 8) | 75.00 % (6 of 8) | 0.00 % (0 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
DVA Stock Performance relative to its Competitors
DVA Stock Performance relative to High-Confidence Competitors
DVA Stock Performance relative to Similar-Size Competitors
DVA Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Rockwell Medical inc | 282.9% | Outperformed |
| 2 | National Healthcare Corp | 282.9% | Outperformed |
| 3 | Aveanna Healthcare Holdings Inc | 282.9% | Outperformed |
| 4 | Tenet Healthcare Corp | 282.9% | Outperformed |
| 5 | Quest Diagnostics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Davita Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Davita Inc's Comment on Competition and Industry Peers
U.S. and International dialysis competition
The U.S. dialysis industry has consolidated significantly over time but still
remains highly competitive, particularly in terms of acquiring existing outpatient
dialysis centers. We continue to face a high degree of competition in the U.S.
dialysis industry from large and medium-sized providers who compete directly
with us for the acquisition of dialysis businesses, relationships with physicians
to act as medical directors and for individual patients. In addition, as we
continue our international dialysis expansion into various international markets,
we will face competition from large and medium-sized providers for these acquisition
targets as well. Because of the ease of entry into the dialysis business and
the ability of physicians to be medical directors for their own centers, competition
for growth in existing and expanding markets is not limited to large competitors
with substantial financial resources. Acquisitions, developing new outpatient
dialysis centers, patient retention and physician relationships are a critical
component of our growth strategy and our business could be adversely affected
if we are not able to continue to make acquisitions on reasonable terms, continue
to develop new dialysis centers, maintain or establish new relationships with
physicians or if we experience significant patient attrition to our competitors.
Competition for qualified physicians to act as medical directors and for inpatient
dialysis services agreements with hospitals is also intense. Occasionally, we
have also experienced competition from former medical directors or referring
physicians who have opened their own dialysis centers. In addition, we experience
competitive pressures in connection with negotiating contracts with commercial
healthcare payors.
The two largest dialysis companies, FMC and our company, account for approximately
71% of outpatient dialysis patients in the U.S. with our company serving approximately
35% of the total outpatient dialysis patients. Approximately 44% of the centers
not owned by us or FMC are owned or controlled by hospitals or non-profit organizations.
Hospital-based and non-profit dialysis units typically are more difficult to
acquire than physician-owned centers.
HCP’s competition
HCP’s business is highly competitive. HCP competes with managed care organizations,
hospitals, medical groups and individual physicians in its markets. HCP competes
with other primary care physician groups or physicians who contract with health
plans for membership. Health plans contract with care providers on the basis
of costs, reputation, scope, efficiency and stability. Individual members select
a primary care physician at the time of membership with the health plan. Location,
name recognition, quality indicators and other factors go into that decision.
For example, in California, HCP competes with both Permanente Medical Group,
which is the exclusive provider for Kaiser, and Heritage Provider Network. However,
HCP’s principal competitors for members and health plan contracts vary
by market.
Corporate compliance program
Our businesses are subject to extensive federal, state and local government
regulations. Management has designed and implemented a corporate compliance
program as part of our commitment to comply fully with all applicable laws and
regulations and to maintain the high standards of conduct we expect from all
of our teammates. We continuously review this program and enhance it as necessary.
The primary purposes of the program include:
Assessing and identifying risks for existing and new businesses, such as HCP;
Increasing, through training and education, the awareness of our teammates and affiliated professionals of the necessity of complying with all applicable laws, regulations and company policies and procedures;
Auditing and monitoring the activities of our operating units and business support functions on a regular basis to identify potential instances of noncompliance in a timely manner; and
Ensuring that we take steps to resolve instances of noncompliance or to address areas of potential noncompliance as promptly as we become aware of them.
We have a code of conduct that each of our teammates and affiliated professionals must follow and we have a confidential toll-free hotline for teammates and patients to report potential instances of noncompliance. Our Chief Compliance Officer administers the compliance program. The Chief Compliance Officer reports directly to our Chief Operating Officer and to the Compliance Committee of our Board of Directors.
Publicly Traded Peers of Davita Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Davita Inc | 11,600.47 | 14,009.65 |
| Hca Healthcare Inc | 97,600.88 | 76,388.00 |
| Quest Diagnostics Inc | 26,445.44 | 11,560.00 |
| Tenet Healthcare Corp | 21,681.52 | 21,812.00 |
| Fresenius Medical Care Ag | 12,998.75 | 21,982.91 |
| Encompass Health Corporation | 12,272.50 | 6,206.10 |
| SUBTOTAL | 211,592.86 | 210,810.96 |
Sign in to see all competitors of Davita Inc .
Sources: Davita Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Davita Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Davita Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Nuwellis Inc | Named by the company | 85% |
| Unicycive Therapeutics Inc | Named by the company | 85% |
| Astrana Health Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Davita Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Davita Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Davita Inc | U. S. Dialysis And Related Lab Services 84.42 % |
| Hca Healthcare Inc | American Group 34.90 % |
| Quest Diagnostics Inc | Diagnostic Information Services Business 97.86 % |
| Tenet Healthcare Corp | Hospital Operations 75.34 % |
| Encompass Health Corporation | Inpatient Rehabilitation 100.00 % |
| Universal Health Services Inc | Acute Care Hospital Services 56.27 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Davita Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Davita Inc | 11,600 | 179,611 | 15,250 |
| Hca Healthcare Inc | 97,601 | 238,713 | 24,419 |
| Quest Diagnostics Inc | 26,445 | 202,807 | 19,526 |
| Tenet Healthcare Corp | 21,682 | 220,323 | 32,061 |
| Fresenius Medical Care Ag | 12,999 | 200,395 | 12,163 |
| Encompass Health Corporation | 12,273 | 147,764 | 19,840 |
| PEERS TOTAL | 199,992 | 225,982 | 18,492 |
Davita Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Rockwell Medical inc | United States 86.19 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Davita Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 48 companies in Davita Inc's industry classification, broader than the peer set above. Market cap in millions of $.Davita Inc ranks #6 of 48 companies by market capitalization in its industry, holding 4.62 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,725, indicating a moderately concentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Hca Healthcare Inc | 98,050 | 38.48 % |
| 2 | Tenet Healthcare Corp | 21,657 | 8.50 % |
| 3 | Fresenius Medical Care Ag | 13,366 | 5.25 % |
| 4 | Brightspring Health Services Inc | 12,454 | 4.89 % |
| 5 | Encompass Health Corporation | 1,234 | 5.2% |
| 6 | Davita Inc | 11,769 | 4.62 % |
| 7 | Universal Health Services Inc | 1,234 | 5.2% |
| 8 | Ensign Group Inc | 1,234 | 5.2% |
| 9 | Pacs Group Inc | 1,234 | 5.2% |
| 10 | Chemed Corporation | 1,234 | 5.2% |
Market cap and industry share for the rest of Davita Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-28.
Davita Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 1 | Hca Healthcare Inc | 98,050 | 6.81 % |
| 2 | Tenet Healthcare Corp | 21,657 | 34.75 % |
| 3 | Fresenius Medical Care Ag | 13,366 | -8.53 % |
| 4 | Brightspring Health Services Inc | 12,454 | 112.01 % |
| 5 | Encompass Health Corporation | 1,234 | 12.3% |
| 6 | Davita Inc | 11,769 | 38.87 % |
| 7 | Universal Health Services Inc | 1,234 | 12.3% |
| 8 | Ensign Group Inc | 1,234 | 12.3% |
| 9 | Pacs Group Inc | 1,234 | 12.3% |
| 10 | Chemed Corporation | 1,234 | 12.3% |
| 11 | Hims and Hers Health Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Davita Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-28. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Davita Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Healthcare Facilities industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (77 companies). See the full Healthcare Facilities industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | - | 52.28 % (avg) | - |
| Operating Margin | 15.19 % | industry median | +7.8 pp |
| EBITDA Margin | 13.37 % | 3.22 % (avg) | +10.1 pp |
| Capital Intensity (Capex / Revenue) | 4.16 % | 4.01 % (avg) | +0.2 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Davita Inc's Valuation vs Competitive Position
Valuation multiples vs the Healthcare Facilities industry average (77 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Healthcare Facilities industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 12.9x | 23.5x | -10.7x |
| EV / EBITDA | 14.1x | 15.7x | -1.6x |
| P/B | -29.0x | 3.3x | -32.3x |
| Return on Equity | -247.90 % | industry aggregate | -272.70 % |
| Return on Invested Capital | 12.74 % | 4.91 % (avg) | 7.83 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Davita Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | -31.55 % | -18.78 % | 1.42 % | 0.59 % | -0.08 % | 4.57 % | 5.56 % | 6.46 % |
| Operating Margin | 10.88 % | 14.43 % | 14.67 % | 15.47 % | 11.53 % | 13.20 % | 16.31 % | 14.98 % |
| Return on Invested Capital | 7.97 % | 9.14 % | 9.65 % | 10.38 % | 8.26 % | 9.83 % | 13.18 % | 13.70 % |
| P/E | 74.7x | 13.8x | 17.9x | 12.1x | 12.8x | 13.7x | 11.1x | 8.2x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Davita Inc's Strategic Group Map
Every company in Davita Inc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Davita Inc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Davita Inc's BCG Growth-Share Matrix
Relative market share (vs Davita Inc's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Davita Inc falls in the Dog quadrant: relative market share of 0.12x vs its largest competitor, in an industry growing revenue 4.2% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution. A caveat worth reading alongside this chart: Hca Healthcare Inc alone holds 38% of this industry's market cap. In an industry this dominated by one leader, the framework will place nearly every OTHER company in "Dog" or "Question Mark" purely because relative share is measured against that leader, regardless of how strong those other companies actually are on their own fundamentals. Check the Profitability, Valuation and Financial Strength sections above before treating this quadrant label as a verdict.
Davita Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | Moderate | Industry HHI of 1,725 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Moderate, in line with the industry | Capital intensity (capex / revenue) of 4.16 % vs industry average 4.01 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Davita Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Davita Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Davita Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Davita Inc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Davita Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 7.8 points above the industry median.
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Return on equity 272.7 points below the industry aggregate.
- Low relative market share vs the industry leader (0.12x).
Opportunities
- Trades at a lower P/E than the industry average (12.9x vs 23.5x) despite a higher return on invested capital -- a possible re-rating opportunity.
Threats
- Industry dominated by Hca Healthcare Inc , holding 38.48 % of industry market cap.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Davita Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Davita Inc | 0.23 | 1.38 | - |
| Hca Healthcare Inc | 0.06 | 0.90 | - |
| Quest Diagnostics Inc | 0.22 | 1.22 | 0.76 |
| Tenet Healthcare Corp | 0.53 | 1.54 | 3.16 |
| Fresenius Medical Care Ag | 0.26 | 1.26 | 0.40 |
| Encompass Health Corporation | 0.10 | 1.15 | 0.98 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Davita Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Davita Inc | Q2 2026 | +5.2 % | +24.7 % |
| Hca Healthcare Inc | Q1 2026 | +4.3 % | +1.8 % |
| Quest Diagnostics Inc | Q2 2026 | +10.2 % | +12.8 % |
| Tenet Healthcare Corp | Q2 2026 | +6.8 % | +100.2 % |
| Fresenius Medical Care Ag | Q4 2025 | +1.5 % | +60.8 % |
| Encompass Health Corporation | Q2 2026 | +9.6 % | +12.2 % |
| PEERS TOTAL | +3.5 % | +18.7 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Davita Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Davita Inc | Q2 2026 | - | +40.2 % |
| Hca Healthcare Inc | Q1 2026 | - | +12.9 % |
| Quest Diagnostics Inc | Q2 2026 | +10.9 % | +27.8 % |
| Tenet Healthcare Corp | Q2 2026 | +14.4 % | -13.0 % |
| Fresenius Medical Care Ag | Q4 2025 | +0.1 % | - |
| Encompass Health Corporation | Q2 2026 | - | +40.4 % |
Davita Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Davita Inc | 6.77% | 6.92% | - |
| Hca Healthcare Inc | 12.94% | 18.54% | - |
| Quest Diagnostics Inc | 6.74% | 8.05% | 14.85% |
| Tenet Healthcare Corp | 10.49% | 9.98% | 50.64% |
| Fresenius Medical Care Ag | 3.84% | 4.81% | 8.34% |
| Encompass Health Corporation | 11.60% | 11.56% | 25.52% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Davita Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Davita Inc | 10.71 | 0.83 |
| Hca Healthcare Inc | 14.96 | 1.28 |
| Quest Diagnostics Inc | 25.01 | 2.29 |
| Tenet Healthcare Corp | 7.10 | 0.99 |
| Fresenius Medical Care Ag | 11.75 | 0.59 |
| Encompass Health Corporation | 19.99 | 1.98 |
| PEERS AVERAGE | 12.24 | 1.00 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.
